New York State Common Retirement Fund lowered its position in QuidelOrtho Co. (NASDAQ:QDEL – Free Report) by 9.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 101,580 shares of the company’s stock after selling 10,877 shares during the quarter. New York State Common Retirement Fund owned about 0.15% of QuidelOrtho worth $7,419,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the company. Money Concepts Capital Corp grew its holdings in shares of QuidelOrtho by 66.8% in the fourth quarter. Money Concepts Capital Corp now owns 337 shares of the company’s stock valued at $29,000 after purchasing an additional 135 shares during the period. Global Retirement Partners LLC grew its holdings in shares of QuidelOrtho by 109.0% in the third quarter. Global Retirement Partners LLC now owns 347 shares of the company’s stock valued at $26,000 after purchasing an additional 181 shares during the period. Arizona State Retirement System grew its holdings in shares of QuidelOrtho by 1.4% in the third quarter. Arizona State Retirement System now owns 14,229 shares of the company’s stock valued at $1,039,000 after purchasing an additional 200 shares during the period. Eagle Bay Advisors LLC grew its holdings in shares of QuidelOrtho by 174.2% in the second quarter. Eagle Bay Advisors LLC now owns 351 shares of the company’s stock valued at $34,000 after purchasing an additional 223 shares during the period. Finally, Oak Family Advisors LLC grew its holdings in shares of QuidelOrtho by 1.6% in the second quarter. Oak Family Advisors LLC now owns 16,771 shares of the company’s stock valued at $1,390,000 after purchasing an additional 263 shares during the period. Hedge funds and other institutional investors own 93.87% of the company’s stock.
QuidelOrtho Trading Up 1.7 %
NASDAQ QDEL opened at $68.15 on Friday. The firm has a 50 day simple moving average of $70.94 and a 200-day simple moving average of $72.17. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.95 and a current ratio of 1.59. QuidelOrtho Co. has a one year low of $57.54 and a one year high of $98.67. The firm has a market cap of $4.55 billion, a price-to-earnings ratio of 358.70 and a beta of 0.21.
Analyst Ratings Changes
QuidelOrtho Company Profile
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Five stocks we like better than QuidelOrtho
- How to Invest in the Best Canadian Stocks
- Cloudflare results spark analysts reset: 25% upside ahead
- The How And Why of Investing in Oil Stocks
- Beyond Nvidia: The hidden stars with 200% earnings growth
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.